This is a study to allow continued treatment for participants enrolled in studies of
BXQ-350. This study is intended only for those who have completed the required study
observation period or are still on treatment upon the closure of their respective BXQ-350
clinical study. The additional treatment is optional and voluntary.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT04404569.
This is an open-label, multi-center, rollover study to allow continued treatment access
for participants enrolled in studies of BXQ-350. This study is intended for subjects who
have completed the required study observation period or are still on treatment upon the
closure of their respective BXQ-350 clinical study, and who are judged by the
Investigator to benefit from continued treatment with BXQ-350. The additional treatment
is optional and voluntary.
This clinical trial information was submitted voluntarily under the applicable law and,
therefore, certain submission deadlines may not apply. (That is, clinical trial
information for this applicable clinical trial was submitted under section 402(j)(4)(A)
of the Public Health Service Act and 42 CFR 11.60 and is not subject to the deadlines
established by sections 402(j)(2) and (3) of the Public Health Service Act or 42 CFR
11.24 and 11.44.)
Lead OrganizationBexion Pharmaceuticals, Inc.
